Literature DB >> 21962504

A blueprint for advancing genetics-based cancer therapy.

William R Sellers1.   

Abstract

In the era of next-generation sequencing, there are significant challenges to harnessing cancer genome information to develop novel therapies. Key research thrusts in both academia and industry will speed this transition, and lessons learned for cancer will more broadly shape the process for genetic contributions to the therapy of disease more broadly.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2011        PMID： 21962504     DOI： 10.1016/j.cell.2011.09.016

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  32 in total

1.  Cancer: Exploiting collateral damage.

Authors:  Ben Lehner; Solip Park
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

Review 2.  Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.

Authors:  P Ramos; M Bentires-Alj
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 3.  Ten things you should know about protein kinases: IUPHAR Review 14.

Authors:  Doriano Fabbro; Sandra W Cowan-Jacob; Henrik Moebitz
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 8.739

Review 4.  Cooperation and antagonism among cancer genes: the renal cancer paradigm.

Authors:  Samuel Peña-Llopis; Alana Christie; Xian-Jin Xie; James Brugarolas
Journal:  Cancer Res       Date:  2013-07-05       Impact factor: 12.701

5.  Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

Authors:  Marta Chesi; Geoffrey M Matthews; Victoria M Garbitt; Stephen E Palmer; Jake Shortt; Marcus Lefebure; A Keith Stewart; Ricky W Johnstone; P Leif Bergsagel
Journal:  Blood       Date:  2012-03-26       Impact factor: 22.113

Review 6.  Next generation sequencing and a new era of medicine.

Authors:  Graham Casey; David Conti; Robert Haile; David Duggan
Journal:  Gut       Date:  2012-05-01       Impact factor: 23.059

Review 7.  Combinatorial drug therapy for cancer in the post-genomic era.

Authors:  Bissan Al-Lazikani; Udai Banerji; Paul Workman
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

8.  PUMA and BIM are required for oncogene inactivation-induced apoptosis.

Authors:  Gregory R Bean; Yogesh Tengarai Ganesan; Yiyu Dong; Shugaku Takeda; Han Liu; Po M Chan; Yafen Huang; Lewis A Chodosh; Gerard P Zambetti; James J-D Hsieh; Emily H-Y Cheng
Journal:  Sci Signal       Date:  2013-03-26       Impact factor: 8.192

9.  Molecular genetics of clear-cell renal cell carcinoma.

Authors:  James Brugarolas
Journal:  J Clin Oncol       Date:  2014-05-12       Impact factor: 44.544

10.  Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Authors:  Igor Vivanco; H Ian Robins; Daniel Rohle; Carl Campos; Christian Grommes; Phioanh Leia Nghiemphu; Sara Kubek; Barbara Oldrini; Milan G Chheda; Nicolas Yannuzzi; Hui Tao; Shaojun Zhu; Akio Iwanami; Daisuke Kuga; Julie Dang; Alicia Pedraza; Cameron W Brennan; Adriana Heguy; Linda M Liau; Frank Lieberman; W K Alfred Yung; Mark R Gilbert; David A Reardon; Jan Drappatz; Patrick Y Wen; Kathleen R Lamborn; Susan M Chang; Michael D Prados; Howard A Fine; Steve Horvath; Nian Wu; Andrew B Lassman; Lisa M DeAngelis; William H Yong; John G Kuhn; Paul S Mischel; Minesh P Mehta; Timothy F Cloughesy; Ingo K Mellinghoff
Journal:  Cancer Discov       Date:  2012-03-31       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.